We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+51.26%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$64.3M
Cap. Flow
+$3.2M
Cap. Flow %
1.14%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$6.07M

Top Sells

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$2.28M
2
ARTV
Artiva Biotherapeutics
ARTV
+$580K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.46B
$131M 46.72%
4,639,304
– –
ALMS
2
Alumis Inc
ALMS
$3.23B
$99.8M 35.56%
4,528,408
-91,395
-2% -$2.28M
ALXO icon
3
ALX Oncology
ALXO
$271M
$25.8M 9.21%
12,884,638
+3,184,713
+33% +$6.07M
HRMY icon
4
Harmony Biosciences
HRMY
$2.22B
$13.7M 4.88%
489,194
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$342M
$6.77M 2.41%
337,697
– –
ARTV
6
Artiva Biotherapeutics
ARTV
$560M
$3.42M 1.22%
531,337
-117,170
-18% -$580K

Similar funds

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $515M AUM 36.69% 1-Year Est. Return
AGC
Aspen Grove Capital Avon, Colorado $514M AUM 21.8% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
TM
Taproot Management New York $530M AUM
UFF
USA Financial Formulas Ada, Michigan $531M AUM 28.6% 1-Year Est. Return
KI
Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return
MCCP
Mission Creek Capital Partners San Francisco, California $501M AUM 28.4% 1-Year Est. Return

venBio Partners's Q1 2026 Portfolio in Review

As of Q1 2026, venBio Partners held 6 positions worth $281M, up 30% from $216M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2026: portfolio turnover was 0%. venBio Partners opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners added most to ALX Oncology in Q1 2026, an estimated $6.07M increase.
  • venBio Partners's biggest Q1 2026 reduction was Alumis Inc, cutting an estimated $2.28M.
  • venBio Partners's ten largest holdings make up 100% of its $281M portfolio in Q1 2026.
  • venBio Partners opened 0 new positions and closed 0 in Q1 2026.
  • venBio Partners's portfolio value rose 30% quarter-over-quarter to $281M.

Based on venBio Partners's 13F filing for Q1 2026, filed 15 May 2026.